The first State of the Union address of his second term saw President Donald Trump return to familiar themes regarding healthcare, prominently touting efforts to lower prescription drug costs. However, even as the President highlighted these achievements, data indicates that over half of Americans continue to find healthcare increasingly unaffordable, according to a recent Kaiser Family Foundation poll.
During his speech, Trump asserted that his administration had brought prescription drug costs down to the lowest levels globally, attributing this success to his “most favored nation” policy. He urged Congressional Republicans to formally codify this policy into law, warning that a future administration might reverse these gains. However, a STAT analysis published February 6, 2026, found that many drugs available through the TrumpRx discount program are, in fact, available as cheaper generics elsewhere, casting doubt on the extent of the savings touted by the President.
Beyond drug pricing, Trump outlined plans to shift government funding away from premium tax credits towards health savings accounts, promised increased efforts to combat fraud within government healthcare programs, and stated his belief that states should not be able to make decisions regarding gender-affirming care without parental consent. Notably absent from the address were discussions surrounding ongoing debates within his administration’s Department of Health and Human Services (HHS), including evolving vaccine mandates and proposed cuts to health and science funding. A comprehensive rundown of the President’s remarks on health policy can be found on STAT News.
Vaccine Policy Faces Legal Challenges
While reports have suggested that Health and Human Services Secretary Robert F. Kennedy Jr. May be shifting his focus away from vaccine policy, legal challenges continue to mount. Fifteen states filed a lawsuit against HHS yesterday, February 24, 2026, challenging the administration’s recent changes to federal vaccine recommendations, as reported by the New York Times.
This legal action coincides with other developments in the vaccine landscape. The Centers for Disease Control and Prevention (CDC) has rescheduled its Advisory Committee on Immunization Practices (ACIP) meeting for March 18-19, following a previously cancelled February meeting, according to the CDC website. However, the meeting’s future remains uncertain, as a judge could potentially weigh in on the matter. The American College of Obstetricians and Gynecologists (ACOG) withdrew its participation as a liaison organization to ACIP yesterday, citing concerns that recent changes “undermine the committee’s scientific integrity and evidence-based approach to vaccine policy,” according to a press release. This follows previous decisions last summer to exclude medical liaisons from the American Medical Association and other groups from the evidence review process.
Cardiovascular Health Concerns for Women
New research published in the journal Circulation projects that six in ten women will develop some form of cardiovascular disease over the next 25 years. The study similarly forecasts that nearly one-third of girls aged 2 to 19 will be classified as obese by 2050. Cardiologist and lead author Karen Joynt Maddox emphasized the implications of these findings, stating, “We’re just setting up a generation of people to move through life having their cardiovascular events earlier and more severe,” as reported by STAT News.
Novo Nordisk Price Cuts and Access to GLP-1s
Novo Nordisk announced yesterday a reduction in the list price of its GLP-1 drugs – Ozempic, Rybelus, and Wegovy – to $675 per month, citing a desire to improve patient access. While this price cut will benefit some patients, particularly those with coinsurance or high-deductible health plans, STAT’s Elaine Chen explains that it may not necessarily lead to broader insurance coverage. The key distinction lies between the list price and the “net price” – the actual cost paid by insurers after rebates and discounts. Further analysis of the potential impact of these price changes can be found on STAT News.
The Role of Dentists in Public Health
Dentists are uniquely positioned to identify early signs of health issues, such as substance use and mental distress, given that many individuals visit their dentist more frequently than their primary care physician. Dentist Divya Upadhyay argues in a recent First Opinion essay that dental procedures should also serve as opportunities for prevention, screening, education, and referral for substance use disorders. Read more about this perspective on STAT News.
the University of Minnesota’s Center for Infectious Disease Research and Policy is releasing a three-part series this week examining the life-threatening risks associated with clindamycin, the second-most prescribed antibiotic for dental procedures. The series can be found on the CIDRAP website.
What We’re Reading
-
The protein bar delusion, The Atlantic
-
After botulism treatment, babies get a treasured birthday card from California program, AP News
- First Opinion: The Rural Health Transformation Program could fail patients like mine, STAT
- Gene therapy is transforming lives, but for many Americans it’s hard to reach, NPR
- Drugmakers lay out their legal arguments against Trump’s drug pricing experiments, STAT
Looking ahead, the CDC’s Advisory Committee on Immunization Practices is scheduled to meet again on March 18-19, though the outcome of ongoing legal challenges could impact the proceedings. The debate surrounding vaccine policy, drug pricing, and access to healthcare will undoubtedly continue to shape the health landscape in the coming months.
What are your thoughts on these developments? Share your comments below.
